METAB-BALANCE Study

Study Overview

A randomized controlled trial comparing a novel GLP-1 receptor agonist with existing standard of care for glycemic control in patients with type 2 diabetes. Secondary endpoints include weight loss and cardiovascular markers.

Inclusion Criteria

• ✓Adults aged 25-70 years
• ✓Type 2 diabetes diagnosis for at least 1 year
• ✓HbA1c between 7.5-10%
• ✓BMI ≥27 kg/m²

Exclusion Criteria

• ✗Type 1 diabetes
• ✗History of pancreatitis
• ✗Severe gastroparesis
• ✗Current insulin therapy